Is Myovant's New Prostate Cancer Drug a Game Changer?

A number of biotech stocks have made major moves over the past week. One of those was Myovant Sciences (NYSE: MYOV), a $1.1 billion biopharma company, which had its shares more than double on Nov. 19 following impressive clinical trial results in treating early, androgen-sensitive prostate cancer.